At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
Docetaxel +3 moredrug
Likely dose
Docetaxel 40mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study Investigating CHFR Methylation Status As A Biomarker For Taxane Sensitivity Using Modified Docetaxel, Cisplatin and 5 Fluorouracil In Patients With Metastatic Esophageal, Gastroesophageal And Gastric Cancer.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Oct 26, 2012·Updated Mar 15, 2019
In Brief
A Phase 2 clinical trial evaluating Docetaxel, Leucovorin, and 2 other interventions for Metastatic Esophageal Cancer and 2 related conditions. Completed, enrolled 27 participants across 1 site.
Detailed Summary
To estimate and compare the response rates in patients treated with mDCF based on methylation status of CHFR.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 2012
Enrollment StartDec 2012
Primary CompletionJun 2015
Study CompletionApr 2017
TodayJul 2026
First PostedOct 26, 2012
Enrollment StartDec 1, 2012
Primary CompletionJun 1, 2015
Study CompletionApr 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 13.7 years ago
Interventions
Docetaxeldrug
Modified Docetaxel 40mg/m2 on Day 1
Leucovorindrug
Leucovorin 400mg/m2 on Day 1
Fluorouracildrug
Fluorouracil 400mg/m2 on Day 1 Fluorouracil 1000mg/m2/day on Days 1 and 2
Cisplatindrug
Cisplatin (or Carboplatin) 40mg/m2 on Day 3